644:
31:
178:
162:
150:
177:
161:
495:
452:
Seger D, Kahn S, Krenzelok EP (2005). "Treatment of US crotalidae bites: comparisons of serum and globulin-based polyvalent and antigen-binding fragment antivenins".
596:
305:
149:
511:"Principles of antidote pharmacology: an update on prophylaxis, post‐exposure treatment recommendations and research initiatives for biological agents"
304:, an antigen over-expressed in 95% of colorectal cancers. It is conjugated to a radioactive element, which will label the tumors when viewed with
273:
589:
706:
67:
391:
359:
559:
W. J. Köstler, C. C. Zielinski (November 2000). "Diagnostische und therapeutische Antikörper in der
Onkologie — State of the Art".
319:
Fab fragments are often fused to small proteins (<100 kDa) that have lower scattering, resulting in images with less contrast.
257:
712:
696:
670:
625:
582:
328:
197:
200:(scFv), which is only half the size of the Fab fragment, yet retains the original specificity of the parent immunoglobulin.
349:
285:
718:
59:
55:
660:
652:
301:
230:
233:
has also been produced but are yet to see approval. Compared to whole non-human antibodies, Fab' and F(ab')
701:
631:
123:
574:
676:
489:
249:
269:
643:
841:
752:
606:
407:
Flanagan RJ, Jones AL (2004). "Fab antibody fragments: some applications in clinical toxicology".
477:
434:
277:
218:
214:
30:
770:
469:
426:
387:
355:
762:
610:
530:
522:
461:
418:
128:
375:
509:
Ramasamy, S; Liu, Cq; Tran, H; Gubala, A; Gauci, P; McAllister, J; Vo, T (October 2010).
17:
535:
510:
121:
has been commercially available. The enzyme IdeS (Immunoglobulin degrading enzyme from
102:
835:
810:
736:
526:
465:
422:
481:
438:
196:
The variable regions of the heavy and light chains can be fused together to form a
380:
313:
297:
265:
238:
222:
281:
226:
71:
820:
795:
790:
309:
253:
242:
91:
473:
430:
105:
monomer into two Fab fragments and an Fc fragment. Conversely, the enzyme
815:
688:
409:
261:
63:
47:
54:. It is composed of one constant and one variable domain of each of the
785:
780:
775:
79:
75:
51:
805:
800:
184:
168:
155:
Heavy and light chains, variable and constant regions of an antibody.
117:
and a pFc' fragment. Recently another enzyme for generation of F(ab')
106:
98:
95:
549:
Fachinformation
Lucentis. Novartis Pharma. Stand 15. November 2007.
140:
29:
578:
316:, is used to label out infections, again using the Tc isotope.
284:, and it treats various inflammatory disorders by binding away
171:
yields three fragments: two Fab fragments and one Fc fragment
109:
cleaves below the hinge region, so the result instead is a
94:
and Fab fragments can be generated in the laboratory. The
312:, an antigen that recognizes proteins on the surface of
131:
in a sequence specific manner at neutral pH. The F(ab')
276:, a protein involved in the growth of blood vessels.
761:
745:
729:
697:
Single-chain variable fragment / di-scFv / tri-scFv
687:
651:
617:
379:
66:(the antigen-binding site), comprising a set of
34:Structure of a Fab with light and heavy chains.
217:as an antidote. Marketed applications include
590:
8:
494:: CS1 maint: multiple names: authors list (
597:
583:
575:
306:single-photon emission computed tomography
256:, which inhibits blood clotting, works by
27:Part of an antibody that binds to antigens
534:
296:Fab antibodies also have diagnostic use.
351:Immunocytochemistry: Theory and practice
252:designated for therapeutic use. The Fab
340:
213:Fabs have seen some therapeutic use in
145:
487:
237:antibodies are less likely to trigger
348:Larsson, Lars-Inge (September 1988).
7:
386:(5th ed.). Garland Publishing.
300:is a mouse antibody that recognizes
274:vascular endothelial growth factor A
68:complementarity-determining regions
62:. The variable domain contains the
707:Small modular immunopharmaceutical
248:Fabs are a common form-factor for
221:and Crofab, a mixture of Fabs for
78:. Each arm of the Y thus binds an
25:
127:, trade name FabRICATOR) cleaves
642:
527:10.1111/j.1476-5381.2010.00939.x
466:10.2165/00139709-200524040-00002
423:10.2165/00002018-200427140-00004
176:
160:
148:
515:British Journal of Pharmacology
258:disabling glycoprotein IIb/IIIa
135:fragment can be split into two
40:fragment antigen-binding region
329:Fragment crystallizable region
198:single-chain variable fragment
187:yields two fragments: a F(ab')
1:
191:fragment and a pFc' fragment
90:In an experimental setting,
858:
640:
561:Acta Chirurgica Austriaca
241:, as the species-related
231:tricyclic antidepressants
101:can be used to cleave an
665:fragment / Fab' fragment
354:. Crc Press. p. 1.
302:carcinoembryonic antigen
282:chemically linked to PEG
183:An antibody digested by
167:An antibody digested by
18:Fragment antigen binding
702:Single-domain antibody
632:Trifunctional antibody
378:; et al. (2001).
124:Streptococcus pyogenes
35:
811:Kunitz domain peptide
677:Chemically linked Fab
607:monoclonal antibodies
250:monoclonal antibodies
33:
270:macular degeneration
225:bites. Fabs against
46:) is a region on an
278:Certolizumab pegol
268:, a treatment for
219:digoxin immune fab
215:emergency medicine
139:fragments by mild
72:amino terminal end
36:
829:
828:
771:Affibody molecule
763:Antibody mimetics
689:Variable fragment
611:antibody mimetics
417:(14): 1115–1133.
16:(Redirected from
849:
646:
599:
592:
585:
576:
569:
568:
556:
550:
547:
541:
540:
538:
506:
500:
499:
493:
485:
449:
443:
442:
404:
398:
397:
385:
372:
366:
365:
345:
180:
164:
152:
82:on the antigen.
21:
857:
856:
852:
851:
850:
848:
847:
846:
832:
831:
830:
825:
757:
741:
725:
683:
664:
647:
638:
613:
603:
573:
572:
558:
557:
553:
548:
544:
508:
507:
503:
486:
451:
450:
446:
406:
405:
401:
394:
376:Janeway, CA Jr.
374:
373:
369:
362:
347:
346:
342:
337:
325:
294:
236:
211:
206:
192:
190:
181:
172:
165:
156:
153:
134:
120:
114:
88:
28:
23:
22:
15:
12:
11:
5:
855:
853:
845:
844:
834:
833:
827:
826:
824:
823:
818:
813:
808:
803:
798:
793:
788:
783:
778:
773:
767:
765:
759:
758:
756:
755:
749:
747:
743:
742:
740:
739:
733:
731:
727:
726:
724:
723:
722:
721:
719:T-cell engager
709:
704:
699:
693:
691:
685:
684:
682:
681:
680:
679:
667:
662:
657:
655:
649:
648:
641:
639:
637:
636:
635:
634:
621:
619:
618:Whole antibody
615:
614:
604:
602:
601:
594:
587:
579:
571:
570:
551:
542:
521:(4): 721–748.
501:
460:(4): 217–227.
444:
399:
392:
367:
360:
339:
338:
336:
333:
332:
331:
324:
321:
293:
290:
234:
210:
207:
205:
202:
194:
193:
188:
182:
175:
173:
166:
159:
157:
154:
147:
132:
118:
112:
103:immunoglobulin
87:
84:
50:that binds to
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
854:
843:
840:
839:
837:
822:
819:
817:
814:
812:
809:
807:
804:
802:
799:
797:
794:
792:
789:
787:
784:
782:
779:
777:
774:
772:
769:
768:
766:
764:
760:
754:
751:
750:
748:
746:Intracellular
744:
738:
737:Microantibody
735:
734:
732:
730:Smaller units
728:
720:
717:
716:
715:
714:
710:
708:
705:
703:
700:
698:
695:
694:
692:
690:
686:
678:
675:
674:
673:
672:
668:
666:
659:
658:
656:
654:
650:
645:
633:
630:
629:
628:
627:
623:
622:
620:
616:
612:
608:
600:
595:
593:
588:
586:
581:
580:
577:
567:(6): 260–263.
566:
562:
555:
552:
546:
543:
537:
532:
528:
524:
520:
516:
512:
505:
502:
497:
491:
483:
479:
475:
471:
467:
463:
459:
455:
448:
445:
440:
436:
432:
428:
424:
420:
416:
412:
411:
403:
400:
395:
393:0-8153-3642-X
389:
384:
383:
382:Immunobiology
377:
371:
368:
363:
361:0-8493-6078-1
357:
353:
352:
344:
341:
334:
330:
327:
326:
322:
320:
317:
315:
311:
307:
303:
299:
291:
289:
287:
283:
279:
275:
271:
267:
263:
259:
255:
251:
246:
244:
240:
232:
228:
224:
220:
216:
208:
203:
201:
199:
186:
179:
174:
170:
163:
158:
151:
146:
144:
142:
138:
130:
126:
125:
116:
108:
104:
100:
97:
93:
85:
83:
81:
77:
73:
69:
65:
61:
57:
53:
49:
45:
41:
32:
19:
711:
669:
653:Fab fragment
624:
564:
560:
554:
545:
518:
514:
504:
490:cite journal
457:
453:
447:
414:
408:
402:
381:
370:
350:
343:
318:
314:granulocytes
295:
247:
245:is removed.
212:
209:Therapeutics
204:Applications
195:
136:
122:
110:
89:
43:
39:
37:
605:Engineered
454:Toxicol Rev
298:Arcitumomab
292:Diagnostics
266:Ranibizumab
239:anaphylaxis
223:rattlesnake
86:Preparation
60:light chain
842:Antibodies
713:bispecific
671:bispecific
626:bispecific
335:References
272:, targets
227:colchicine
44:Fab region
821:nanoCLAMP
796:Anticalin
791:Alphabody
753:Intrabody
310:Sulesomab
280:is a Fab
262:platelets
260:found on
254:abciximab
243:Fc region
141:reduction
70:, at the
836:Category
816:Monobody
482:44916236
474:16499404
439:40869324
431:15554746
410:Drug Saf
323:See also
115:fragment
64:paratope
58:and the
52:antigens
48:antibody
786:Affitin
781:Affimer
776:Affilin
536:2992890
80:epitope
76:monomer
74:of the
806:DARPin
801:Avimer
661:F(ab')
533:
480:
472:
437:
429:
390:
358:
185:pepsin
169:papain
111:F(ab')
107:pepsin
99:papain
96:enzyme
478:S2CID
435:S2CID
56:heavy
609:and
496:link
470:PMID
427:PMID
388:ISBN
356:ISBN
286:TNFα
229:and
137:Fab'
38:The
531:PMC
523:doi
519:161
462:doi
419:doi
129:IgG
838::
565:32
563:.
529:.
517:.
513:.
492:}}
488:{{
476:.
468:.
458:24
456:.
433:.
425:.
415:27
413:.
308:.
288:.
264:.
143:.
92:Fc
663:2
598:e
591:t
584:v
539:.
525::
498:)
484:.
464::
441:.
421::
396:.
364:.
235:2
189:2
133:2
119:2
113:2
42:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
